Zydus Lifesciences surges on getting final approval from USFDA for Estradiol Transdermal System
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 413.95, up by 2.65 points or 0.64% from its previous closing of Rs. 411.30 on the BSE.
The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 415.45 and Rs. 408.80 respectively. So far 43481 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 415.45 and Rs. 397.80 respectively. The current market cap of the company is Rs. 41809.09 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (USRLD: Vivelle-Dot Transdermal System).
Estradiol Transdermal System is indicated to treat moderate to severe symptoms of menopause which includes feelings of warmth in the face, neck and chest or sudden strong feelings of heat, hot flushes and vaginal dryness in women. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India. The group now has 336 approvals and has so far filed over 431 ANDAs (as of September 30, 2022) since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
